Has David Peichert, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,445 in general payments to David Peichert, MD across 69 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Peichert, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Peichert, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Peichert, MD

Interventional Cardiology · Baltimore, MDNPI 1396739306

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Boston Scientific at 32.7% of the total. That places this record below the midpoint for interventional cardiology clinicians in MD, where the typical reported total is $7,370.

$2,445in general payments, 2019–2025

Across 69 payments — averaging $35.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$799
Edwards Lifesciences$565
Medtronic$474
Abbott$292
Shockwave Medical, Inc$92
Biotronik Inc.$57
plus $166 from 5 others

$6,100in research payments, 2019–2025

Across 3 payments — averaging $2033.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$6K

What the payments were for

Food & beverage$2,43099%
Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	13	$799
Edwards Lifesciences	10	$565
Medtronic	18	$474
Abbott	12	$292
Shockwave Medical, Inc	5	$92
Biotronik Inc.	4	$57
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	2	$57
Stryker	2	$43
Philips North America LLC	1	$26
Inari Medical, Inc.	1	$26
Cardinal Health 200 LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,445 in reported general payments places this provider in the 20th percentile of 71 interventional cardiology providers in Maryland.

See all interventional cardiology providers in Maryland →

Medicare billing

Part B allowed, 2024

$155,151

Medicare patients

535

Services billed

1,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	144	$175,416
XareltoRivaroxaban	52	$66,876
Ranolazine ErRanolazine	17	$4,428
Metoprolol Succinate	227	$4,166
Atorvastatin Calcium	202	$3,466
Losartan Potassium	107	$1,422
Amlodipine Besylate	156	$1,393
ClopidogrelClopidogrel Bisulfate	74	$1,231
Lisinopril	158	$1,081
Terazosin Hcl	45	$1,067
Metoprolol Tartrate	120	$1,065
Carvedilol	89	$860
Pravastatin Sodium	27	$822
Rosuvastatin Calcium	54	$805
Flecainide Acetate	13	$681

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Baltimore

Aloke FinnBaltimore$575K
John WangBaltimore$138K
Diljon ChahalBaltimore$78K
Jon ResarBaltimore$40K
Faisal RahmanBaltimore$36K
Matthew VossBaltimore$33K
Hooman BakhshiBaltimore$32K
Daniel AmbinderBaltimore$32K
Rani HasanBaltimore$22K
Ajar KocharBaltimore$22K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →